The gonadoblastoma locus on the Y chromosome (GBY) predisposes the dysgenetic gonads of XY females to develop in situ tumors. It has been mapped to a critical interval on the short arm and adjacent centromeric region on the Y chromosome. Currently there are five functional genes identified on the GBY critical region, thereby providing likely candidates for this cancer predisposition locus. To evaluate the candidacy of one of these five genes, testis-specific protein Y-encoded (TSPY), as the gene for GBY, expression patterns of TSPY in four gonadoblastoma from three patients were analyzed by immunohistochemistry using a TSPY specific antibody. Results from this study showed that TSPY was preferentially expressed in tumor germ cells of all gonadoblastoma specimens. Additional study on two cases of testicular seminoma demonstrated that TSPY was also abundantly expressed in all stages of these germ cell tumors. The present observations suggest that TSPY may either be involved in the oncogenesis of or be a useful marker for both types of germ cell tumors.    

1.
Adachi Y, Pavlakis GN, Copeland TD: Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia. J biol Chem 269:2258–2262 (1994).
2.
Altman R, Kellogg D: Control of mitotic events by Nap1 and the Gin4 kinase. J Cell Biol 138:119–130 (1997).
3.
Blanar MA, Rutter WJ: Interaction cloning: identification of a helix-loop-helix zipper protein that interacts with c-Fos. Science 256:1014–1018 (1992).
4.
Carlson SG, Eng E, Kim EG, Perlman EJ, Copeland TD, Ballermann BJ: Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms’ tumor. J Am Soc Nephrol 9:1873–1880 (1998).
5.
Conrad C, Hierl T, Glaser B, Taylor K, Zeitler S, Chandley AC, et al: High-resolution fluorescence in situ hybridization of RBM- and TSPY-related cosmids on released Y chromatin in humans and pygmy chimpanzees. Chrom Res 4:201–206 (1996).
6.
Cooke HJ: Y chromosome and male infertility. Rev Reprod 4:5–10 (1999).
7.
Delbridge ML, Lingenfelter PA, Disteche CM, Graves JA: the candidate spermatogenesis gene RBMY has a homologue on the human X chromosome. Nature Genet 22:223–224 (1999).
8.
Herbst H, Kuhler-Obbarius C, Lauke H, Sauter M, Mueller-Lantzsch N, Harms D, et al: Human endogenous retrovirus (HERV)-K transcripts in gonadoblastomas and gonadoblastoma-derived germ cell tumors. Virchows Arch 434:11–15 (1999).
9.
Hildenbrand R, Schröder W, Brude E, Schepler A, König R, Sutte HJ, Arnemann J: Detection of TSPY protein in a unilateral microscopic gonadoblastoma of a Turner patient with a Y-derived marker chromosome. J Path 189:623–626 (1999).
10.
Hussong J, Crussi FG, Chou PM: Gonadoblastoma: immunohistochemical localization of Mullerian-inhibiting substance, inhibin, WT-1, and p53. Mod Pathol 10:1101–1105 (1997).
11.
Iezzoni JC, Kap-Herr C, Golden WL, Gaffey MJ: Gonadoblastomas in 45,X/46,XY mosaicism: analysis of Y chromosome distribution by fluorescence in situ hybridization. Am J clin Pathol 108:197–201 (1997).
12.
Jin P, Hardy S, Morgan DO: Nuclear localization of cyclin B1 controls mitotic entry after DNA damage. J Cell Biol 141:875–885 (1998).
13.
Jorgensen N, Muller J, Jaubert F, Clausen OP, Skakkebaek NE: Heterogeneity of gonadoblastoma germ cells: similarities with immature germ cells, spermatogonia and testicular carcinoma in situ cells. Histopathology 30:177–186 (1997).
14.
Kömüves LG, Hanley K, Jiang Y, Katagiri C, Elias PM, Williams ML, et al: Induction of selected lipid metabolic enzymes and differentiation-linked structural proteins by air exposure in fetal rat skin explants. J Invest Dermatol 112:303–309 (1999).
15.
Lahn BT, Page DC: Functional coherence of the human Y chromosome. Science 278:675–680 (1997).
16.
Lau Y-F, Zhang J: Expression analysis of 31 Y chromosome genes in human prostate cancer. Mol Carcin 27:308–321 (2000).
17.
Lau Y-F: Gonadoblastoma, testicular and prostate cancers, and the TSPY gene. Am J hum Genet 64:921–927 (1999).
18.
Looijenga LH, Oosterhuis JW: Pathogenesis of testicular germ cell tumours. Rev Reprod 4:90–100 (1999).
19.
Page DC: Hypothesis: a Y-chromosomal gene causes gonadoblastoma in dysgenetic gonads. Development 101 Suppl:151–155 (1987).
20.
Ratti A, Stuppiea L, Gatta V, Fogh I, Calabrese G, Pizzuti A, Palka G: Characterization of a new TSPY gene family member in Yq (TSPYq1). Cytogenet Cell Genet 88:159–162 (2000).
21.
Salido EC, Yen PH, Koprivnikar K, Yu LC, Shapiro LJ: The human enamel protein gene amelogenin is expressed from both the X and the Y chromosomes [see comments]. Am J hum Genet 50:303–316 (1992).
22.
Salo P, Kaariainen H, Petrovic V, Peltomaki P, Page DC, de la Chapelle A: Molecular mapping of the putative gonadoblastoma locus on the Y chromosome. Genes Chrom Cancer 14:210–214 (1995).
23.
Schiebel K, Mertz A, Winkelmann M, Glaser B, Schempp W, Rappold G: FISH localization of the human Y-homolog of protein kinase PRKX (PRKY) to Yp11.2 and two pseudogenes to 15q26 and Xq12→q13. Cytogenet Cell Genet 76:49–52 (1997).
24.
Schnieders F, Dork T, Arnemann J, Vogel T, Werner M, Schmidtke J: Testis-specific protein, Y-encoded (TSPY) expression in testicular tissues. Hum Mol Genet 5:1801–1807 (1996).
25.
Scully RE: Gonadoblastoma. A review of 74 cases. Cancer 25:1340–1356 (1970).
26.
Scully RE: Gonadoblastoma: a gonadal tumor related to the dysgerminoma (seminoma) and capable of sex-hormone production. Cancer 6:445–463 (1953).
27.
Shin KS, Shin EY, Bae SC, Kim SR, Jeong GB, Kwak SJ, et al: Expression of SET is modulated as a function of cell proliferation. J Cell Biochem 74:119–126 (1999).
28.
Skakkebaek NE, Berthelsen JG, Giwercman A, Muller J: Carcinoma-in-situ of the testis: possible origin from gonocytes and precursor of all types of germ cell tumours except spermatocytoma. Int J Androl 10:19–28 (1987).
29.
Stuppia L, Gatta V, Gaspari A, Grande R, Morizio E, Fantasia D, Mingarelli R, Calabrese G, Palka G: Molecular characterization of PRY and TTY2 on the human Y chromosome. Am J hum Genet 67 (Supl 2):185 (2000).
30.
Takizawa CG, Weis K, Morgan DO: Ran-independent nuclear import of cyclin B1-Cdc2 by importin beta. Proc natl Acad Sci, USA 96:7938–7943 (1999).
31.
Tsuchiya K, Reijo R, Page DC, Disteche CM: Gonadoblastoma: molecular definition of the susceptibility region on the Y chromosome. Am J hum Genet 57:1400–1407 (1995).
32.
Vogel T, Dittrich O, Mehraein Y, Dechend F, Schnieders F, Schmidtke J: Murine and human TSPYL genes: novel members of the TSPY-SET-NAP1L1 family. Cytogenet Cell Genet 81:265–270 (1998).
33.
Vogt PH, Affara N, Davey P, Hammer M, Jobling MA, Lau YF, et al: Report of the Third International Workshop on Y Chromosome Mapping 1997. Heidelberg, Germany, April 13–16, 1997. Cytogenet Cell Genet 79:1–20 (1997).
34.
von Lindern M, van Baal S, Wiegant J, Raap A, Hagemeijer A, Grosveld G: Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3′ half to different genes: characterization of the set gene. Mol Cell Biol 12:3346–3355 (1992).
35.
Zhang JS, Yang-Feng TL, Muller U, Mohandas TK, de Jong PJ, Lau YF: Molecular isolation and characterization of an expressed gene from the human Y chromosome. Hum Mol Genet 1:717–726 (1992).
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.